Document series
Trial abstracts — page 17
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 17 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| HARMONY-OUTCOMES-QOLprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-CNprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| HARMONY-OUTCOMES-REGIONAL-JPprogramme record | Dulaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Observational | — | 2018 | Very low |
| MMPOWER-2-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-ELDERLYprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| MMPOWER-2-OLEprogramme record | SS-31 (elamipretide) | Phase 2 | Reported | Single-arm open-label | — | 2018 | Very low |
| SUSTAIN-7-ADHERENCEprogramme record | Semaglutide | Phase 3 | Reported | Observational | — | 2018 | Very low |
| SUSTAIN-7-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-ELDERLYprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2018 | Very low |
| SUSTAIN-7-OLEprogramme record | Semaglutide | Phase 3 | Reported | Single-arm open-label | — | 2018 | Very low |
| SUSTAIN-7-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2018 | Very low |
| EXSCEL-BODY-COMPprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-QOLprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| EXSCEL-REGIONAL-CNprogramme record | Exenatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| GSH-PD-PH2-ADHERENCEprogramme record | Glutathione | Phase 2 | Reported | Observational | — | 2017 | Very low |
| GSH-PD-PH2-BIOMARKERprogramme record | Glutathione | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| GSH-PD-PH2-ELDERLYprogramme record | Glutathione | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| GSH-PD-PH2-OLEprogramme record | Glutathione | Phase 2 | Reported | Single-arm open-label | — | 2017 | Very low |
| KISS-PH2-HSDD-ADHERENCEprogramme record | Kisspeptin-10 | Phase 2 | Reported | Observational | — | 2017 | Very low |
| KISS-PH2-HSDD-BIOMARKERprogramme record | Kisspeptin-10 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| KISS-PH2-HSDD-ELDERLYprogramme record | Kisspeptin-10 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
| KISS-PH2-HSDD-OLEprogramme record | Kisspeptin-10 | Phase 2 | Reported | Single-arm open-label | — | 2017 | Very low |
| SCALE-PREDIABETES-BIOMARKERprogramme record | Liraglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2017 | Very low |
page 17 of 30